BIIB - バイオジェン (Biogen Inc.)

BIIBのニュース

   Robert W. Baird Stick to Their Hold Rating for Biogen By Investing.com  2021/10/05 09:11:27 Investing.com
Robert W. Baird Stick to Their Hold Rating for Biogen
   Thomasville National Bank Buys Becton, Dickinson and Co, Atmos Energy Corp, Vanguard ...  2021/10/04 22:38:03 GuruFocus
Related Stocks: BDX , BIV , AGG , IXN , SNV , FB , ATO , PZA , PRU , MUB , RHI , NVDA , SCHW , CCBG , T , LLY , PPG , FDN , VFC , IHI , BIIB , VOD , NNN ,
   Sage, Biogen''s zuranolone shows potential to reduce depressive symptoms  2021/10/04 11:04:01 Seeking Alpha
   Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress  2021/10/04 10:30:00 Business Wire
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE and NEST clinical development progra
   UAE approves use of first, only drug to treat Alzheimer''s  2021/10/03 11:28:06 Khaleej Times
Biogen''s Aduhelm (aducanumab) injections get governemnt go-ahead
   STAT+: Pharmalittle: Biogen yanks Alzheimers paper from JAMA over edits; Pfizer sees $33.5 billion in Covid-19 vax sales  2021/07/28 13:38:05 STAT News
Gayle Smith, head of global Covid-19 response at the State Department, urged U.S. vaccine makers to back low-cost manufacturing hubs overseas.
   The 9 behind-the-scenes professionals you need to know in digital health  2021/07/28 12:46:44 Business Insider
Summary List Placement Hello, Welcome to Insider Healthcare. I''m Lydia Ramsey Pflanzer, and today in healthcare news: We found 9 players working behind the scenes who can make or break a digital health startup ; It''s back to wearing masks indoors, even for those fully vaccinated, CDC says ; Here''s the presentation Deep Genomics used to raise $180 million from investors including SoftBank and Khosla . If you''re new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125 . Let''s get to it As coronavirus cases continue to surge in the US fueled by the Delta variant, the CDC introduced new masking guidelines . Everyone should mask up indoors, whether vaccinated or not , in areas of the country at higher risk from the virus. The CDC also recommended that everyone in K-12 schools wear a mask indoors. CDC Director Rochelle Walensky said on Tuesday that new data about Delta had prompted the change from May, when the CDC had said that masks were no longer necessary for fully vaccinated people.
   Global Adalimumab Market Will Reach $ 28,508.07 Million by 2027||Players-CELLTRION INC., Samsung Bioepis (a subsidiary of Samsung Biologics), Biogen, Coherus BioSciences, Innovent Biologics, Inc., Mylan N.V., Zydus Cadila  2021/07/28 08:26:43 OpenPR
Adalimumab market report presents the best market and business solutions to Pharmaceutical industry in this rapidly revolutionizing market place to thrive in the market. Market definition gives the scope of particular product with respect to the driving factors and restraints
   Emerging Therapies such as TMS-007 (Biogen), Trans-Sodium Crocetinate (TSC) (Diffusion Pharmaceuticals), and others Expected to Positively Impact the Hypoxia Market Scenario in the Upcoming Years  2021/07/27 22:30:03 AB Newswire
   Biogen withdrew paper on Alzheimer''s drug Aduhelm from JAMA after requested edits - Axios  2021/07/27 18:05:38 Seeking Alpha
   Biogen's Retinal Disease Gene Therapy Flunks Mid-Stage Study  2021/05/14 12:30:18 Benzinga
Biogen Inc (NASDAQ: BIIB ) has announced topline results from the Phase 2/3 XIRIUS study evaluating cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). XLRP is a rare, inherited retinal disease associated with progressive vision loss as the retina's light-sensing cells gradually deteriorate. The XIRIUS study did not meet … Full story available on Benzinga.com
   Biogen, Capsigen Ink $1.3B AAV Capsids Development Pact For CNS & Neuromuscular Disorders  2021/05/11 13:05:46 Benzinga
Biogen Inc (NASDAQ: BIIB ) and Capsigen Inc have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids with the potential to deliver gene therapies for various CNS and neuromuscular disorders. As … Full story available on Benzinga.com
   Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End  2021/05/03 10:46:13 Benzinga
Denali Therapeutics Inc (NASDAQ: DNLI ) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The drug is being developed in collaboration with Biogen Inc (NASDAQ: BIIB ). The results will be presented at the International Association of Parkinsonism and Related Disorders Virtual Congress. Results from the Phase 1 study of healthy volunteers (N=184) and the Phase 1b study of patients with Parkinson's disease … Full story available on Benzinga.com
   Biogen's Shares Are Trading Lower On 71% Quarterly Profit Slump, Weak Tecfidera Sales  2021/04/22 14:50:22 Benzinga
Biogen Inc (NASDAQ: BIIB ) reported a 70.7% fall in Q1 profit as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic drugs. Net income fell to $410.2 million, or $2.69 per share for the quarter from $1.40 billion, or $8.08 per share, a year earlier. Adjusted EPS came in at $5.34, down from $9.14 a year ago, but higher than the … Full story available on Benzinga.com
   Biogen quarterly profit slumps about 71% on MS drug competition  2021/04/22 11:30:25 Investing.com
https://www.investing.com/news/stock-market-news/biogen-quarterly-profit-slumps-about-71-on-ms-drug-competition-2482097

calendar